Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A DORIA

Showing results (361-370 of 667) with videos related to

Pageof 67
Sort By:
Cell Reports|April 27, 2017
Quantification of the Impact of the HIV-1-Glycan Shield on Antibody ElicitationTongqing Zhou, Nicole A Doria-Rose, Cheng Cheng, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapyLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
The New England Journal of Medicine|January 26, 2022
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster VaccinationRolando Pajon, Nicole A Doria-Rose, Xiaoying Shen, et al.
Nature Immunology|October 6, 2025
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapyLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variantsLingshu Wang, Tongqing Zhou, Yi Zhang, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus MacaquesHongying Duan, Joseph P Nkolola, Shuishu Wang, et al.
Pageof 67

Showing results (361-370 of 667) with videos related to

Sort By:
Pageof 67
Cell Reports|April 27, 2017
Quantification of the Impact of the HIV-1-Glycan Shield on Antibody ElicitationTongqing Zhou, Nicole A Doria-Rose, Cheng Cheng, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapyLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
The New England Journal of Medicine|January 26, 2022
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster VaccinationRolando Pajon, Nicole A Doria-Rose, Xiaoying Shen, et al.
Nature Immunology|October 6, 2025
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapyLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variantsLingshu Wang, Tongqing Zhou, Yi Zhang, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus MacaquesHongying Duan, Joseph P Nkolola, Shuishu Wang, et al.
Pageof 67